ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the development ...
Single B-cell technologies have emerged as powerful screening tools to accelerate antibody discovery, offering R&D teams the potential to interrogate millions of individual antibody-secreting cells to ...
French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). The company’s tetraspecific antibody controlled tumors and improved survival in mice and ...
Meanwhile, B cells that have yet to win the jackpot continue to roll the dice with drawn-out G0/G1 phases and baseline assistance from T cells. The findings were confirmed in mouse immunization ...
Morning Overview on MSN
Scientists find a way to turbocharge cancer-fighting immunity
Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...
A CAR-T cell product can contain both CAR-T cells and CAR-negative bystander T cells (left). After treatment with CAR-T cell therapy, CAR-T cells kill tumor cells and release a panel of cytokines. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback